Pharma

€15m first tranche of a €35m package to expand a Colombian plant to produce up to 250m doses annually, plus a €1.5m R&D grant for three vaccine candidates.

Tri-specific Wnt-pathway agonist showed non-inferior BCVA gains vs ranibizumab at week 52; higher rates of PDR, vitreous hemorrhage and discontinuations observed.

Passed a two-week unannounced FDA GMP inspection covering drug substance and drug product manufacturing, reinforcing U.S. commercial supply reliability.

FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.

Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.

Interim analysis shows significant, clinically meaningful 24‑hour UPCR reduction at 37 weeks; blinded study continues to the eGFR endpoint at week 105.

Phase III interim data show significant proteinuria reduction at 37 weeks; drug targets liver-derived factor B via monthly subcutaneous dosing; blinded follow-up continues to week 105 eGFR.

Phase 3 trial showed rapid, sustained reduction in systemic disease activity in moderate-to-severe Sjögren's disease with manageable safety signals.

Three world-scale acetyls units in Hull mothballed, threatening nearly 4,000 skilled jobs and eliminating Europe’s last large acetyls capacity amid extreme gas-price disparity.

FDA updates PAH therapy label to include HYPERION data showing a 76% reduction in clinical worsening when added to background therapy for patients diagnosed within 12 months.